Pharmaceutical Research Peptide Therapeutics Market 2026 | Page 3

REPORT DESCRIPTION
Key players in the peptide therapeutic market are engaged in expanding market share
through new product launches and regulatory approval. For instance, in March 2016, Eli Lilly
and Company introduced anti-diabetes drug Trulicity (dulaglutide) in India. Trulicity
(dulaglutide) is once-a- week non-insulin injectable belonging to class of drugs called
glucagon-like peptide (GLP-1) receptor agonist, which helps the body to release its own
insulin after the intake of food. In July 2016, U.S. Food and Drug Administration (FDA),
approved Sanofi-Aventis’s Adlyxin (lixisenatide), a once-daily injection to improve glycemic
control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
To know the latest trends and insights related to peptide therapeutics market, click the link
below:
https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837
Peptide therapeutics market is projected to witness lucrative growth over the forecast
period, owing to the various in-organic growth strategies implemented by key manufacturing
players in this market. For instance, in July 2012, Amgen Inc. completed the acquisition of
KAI Pharmaceuticals, Inc. for a deal value of US$ 315 million. During the acquisition, KAI
Pharmaceuticals had a peptide product in development stage: KAI-4169, which is indicated
for the treatment of Secondary Hyperparathyroidism (SHPT) in patients with Chronic Kidney
Disease (CKD) who are on dialysis and is in currently in phase 2 trials. Moreover, this
acquisition allowed Amgen to acquire worldwide rights of KAI-4169, excluding Japan.
Request Customization:
https://www.coherentmarketinsights.com/insight/request-customization/1837
© Coherent market Insights. All Rights Reserved